We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

128 hedge funds and large institutions have $335M invested in Progenics Pharmaceuticals Inc in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 35

2% less capital invested

Capital invested by funds: $343M → $335M (-$8.12M)

5% less funds holding

Funds holding: 135 → 128 (-7)

27% less call options, than puts

Call options by funds: $1.01M | Put options by funds: $1.38M

28% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 25

Holders
128
Holders Change
-7
Holders Change %
-5.19%
% of All Funds
2.52%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
44
Reduced
35
Closed
25
Calls
$1.01M
Puts
$1.38M
Net Calls
-$367K
Net Calls Change
-$1.64M

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$7.81M
2
AA
AQR Arbitrage
Connecticut
+$5.59M
3
FCM
Farallon Capital Management
California
+$4.76M
4
State Street
State Street
Massachusetts
+$3.86M
5
BlackRock
BlackRock
New York
+$3M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.1M
2
RHJA
Rice Hall James & Associates
California
-$8.98M
3
PA
Pinnacle Associates
New York
-$6.43M
4
PFC
Phocas Financial Corp
California
-$5.17M
5
RA
Royce & Associates
New York
-$4.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
26
RhumbLine Advisers
Massachusetts
$1.42M +$97.9K +18,508 +7%
Legal & General Group
27
Legal & General Group
United Kingdom
$1.15M +$89.3K +16,891 +8%
VI
28
Versor Investments
New York
$1.11M +$1.16M +218,975 New
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$997K +$298K +56,384 +40%
Public Sector Pension Investment Board (PSP Investments)
30
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$984K -$123K -23,200 -11%
ERSOT
31
Employees Retirement System of Texas
Texas
$876K – – –
Two Sigma Investments
32
Two Sigma Investments
New York
$868K +$902K +170,480 New
CS
33
Credit Suisse
Switzerland
$848K +$590K +111,557 +202%
Swiss National Bank
34
Swiss National Bank
Switzerland
$842K +$33.9K +6,400 +4%
Wells Fargo
35
Wells Fargo
California
$795K +$220K +41,668 +36%
PPA
36
Parametric Portfolio Associates
Washington
$739K -$142K -26,898 -16%
New York State Teachers Retirement System (NYSTRS)
37
New York State Teachers Retirement System (NYSTRS)
New York
$706K – – –
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$690K – – –
Prudential Financial
39
Prudential Financial
New Jersey
$682K +$2.38K +450 +0.3%
IC
40
Ikarian Capital
Texas
$666K +$692K +130,845 New
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$649K – – –
SW
42
SkyOak Wealth
Michigan
$599K +$622K +117,672 New
Canada Life
43
Canada Life
Manitoba, Canada
$555K +$582K +109,938 New
Fisher Asset Management
44
Fisher Asset Management
Washington
$535K – – –
Allianz Asset Management
45
Allianz Asset Management
Germany
$525K -$2.92K -551 -0.5%
DAM
46
DLD Asset Management
New York
$509K +$529K +100,000 New
Rafferty Asset Management
47
Rafferty Asset Management
New York
$507K -$158K -29,792 -23%
TD Asset Management
48
TD Asset Management
Ontario, Canada
$494K -$36K -6,800 -7%
VEA
49
Virtus ETF Advisers
New York
$419K +$108K +20,460 +33%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$380K -$368K -69,548 -48%
1
2
3 4 5

PGNX Hedge Fund Activity: Q4 2019 in Review

128 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2019, worth a combined $335M — down 2.4% from $343M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of PGNX and 18 opened new positions — a net loss of 7 holders — while 35 trimmed existing stakes and 44 added.

The largest buyer was Broadfin Capital, adding an estimated $7.81M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $14.1M sold.

  • 128 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2019, down from 135 in Q3 2019.
  • Funds reported $335M of Progenics Pharmaceuticals Inc stock for Q4 2019, down 2.4% quarter-over-quarter.
  • 18 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2019 and 25 closed out, a net change of -7 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2019 was Broadfin Capital, an estimated $7.81M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2019 was Point72 Asset Management, an estimated $14.1M sold.

Based on aggregated 13F filings for Q4 2019.